All In Biotech

NDA 203168 · Bausch and Lomb

Prolensa

Bromfenac Sodium · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Feb 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Apr 5, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

15 Phase 3, 1 recruiting

FAERS reports

1,426

682 serious, 39 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2026.

Bromfenac Ophthalmic Solution 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. ( 1 )

Mechanism: Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 5, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • PROLENSA · BROMFENAC SODIUM EQ 0.07% ACID · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bromfenac" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain112
  • off label use105
  • vision blurred104
  • eye irritation95
  • cataract85
  • dizziness59
  • drug ineffective59
  • fatigue59
  • nausea54
  • visual impairment51
  • diarrhoea49
  • headache47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20061
20072
20085
20091
20105
20115
20125
201314
201456
2015110
2016104
2017116
2018139
2019115
2020132
2021129
2022117
2023122
2024107
202585
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prolensa (Bromfenac Sodium)

2024 spending

$44.5M

Beneficiaries

68,899

122,194 claims

Per beneficiary

$645

$114.28 per unit

View as table
YearSpending
2020$61,135,053
2021$76,930,200
2022$88,070,914
2023$94,508,695
2024$44,465,163

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 99 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.